1PC.SG

Pursued progress while ensuring stability and built up momentum, Legend Holdings realized revenue of RMB237,685 million in the first half of 2022

Retrieved on: 
星期三, 八月 31, 2022
University, CEO, Technology, Civilization, Central committee, SME, Corporation, Family Group Conference, EVA, Artificial intelligence, Carbon, Legend Holdings, Lenovo, A Legend Star Entertainment Corp., Luxembourg, USD, Communist party, Policy, Health, Science, Revolutionary Communist Party of China, Investment, Patent, Social responsibility, Medicine, BIL, Leadership, Gartner, Company, Capital, Banque Internationale à Luxembourg, Face, Growth, Empowerment, Environment, Initial public offering, Airline, Management, Renewable energy, Bank, Specialization

During the Reporting Period, the Company's revenue was RMB237,685 million and the net profit attributable to equity holders of the Company amounted to RMB2,131 million.

Key Points: 
  • During the Reporting Period, the Company's revenue was RMB237,685 million and the net profit attributable to equity holders of the Company amounted to RMB2,131 million.
  • During the Reporting Period, Legend Holdings further consolidated the foundation of its industrial operations and strengthened its operational management.
  • The revenue of the segment increased by 4% year-on-year to RMB235,775 million, and the net profit attributable to the equity holders of Legend Holdings increased by 20% year-on-year to RMB2,830 million.
  • Joy Wing Mau continued to improve its vertically integrated fruit supply chain and achieved rapid growth in revenue.

Led by Legend Capital, Multi-omics-leading Enterprise APTBIO Closes Series B with Hundreds of Millions of CNY

Retrieved on: 
星期五, 八月 19, 2022
Map, Precision medicine, AI, Technology, CRO, VC, Research, Life, ESG, Mass spectrometry, Proteomics, CNY, RMB, Health, Biotechnology, UNPRI, Metabolomics, Big data, USD, Fine chemical

HONG KONG, Aug 19, 2022 - (ACN Newswire) - Shanghai Applied Protein Technology Co., Ltd. ("APTBIO"), a leading enterprise focused on mass spectrometry-based multi-omics applied to precision medicine, recently announced the completion of its Series B with hundreds of millions of CNY, which is led by Legend Capital.

Key Points: 
  • HONG KONG, Aug 19, 2022 - (ACN Newswire) - Shanghai Applied Protein Technology Co., Ltd. ("APTBIO"), a leading enterprise focused on mass spectrometry-based multi-omics applied to precision medicine, recently announced the completion of its Series B with hundreds of millions of CNY, which is led by Legend Capital.
  • Ms. CHEN Wei, the founder of APTBIO, said: "I would like to take this opportunity to extend my sincere gratitude to our investors.
  • Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add.
  • As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully

Retrieved on: 
星期一, 八月 15, 2022
ChiNext, Industry, R, CRO, Clinical trial, VC, Data management, ESG, WuXi AppTec, WuXi Biologics, D, RMB, Health, Series, UNPRI, Shenzhen Stock Exchange, USD, Fine chemical, Bellen

HONG KONG, Aug 15, 2022 - (ACN Newswire) - On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange.

Key Points: 
  • HONG KONG, Aug 15, 2022 - (ACN Newswire) - On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange.
  • Legend Capital invested in the Series A round of R&G PharmaStudies in the second half of 2017 and has kept on supporting the development of R&G PharmaStudies.
  • Jafar Wang, the Co-Chief Investment Officer of Legend Capital, said, "Congratulations on the successful listing of R&G PharmaStudies!
  • As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.